Cargando…

Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches

SIMPLE SUMMARY: When we ingest a meal, our intestine secretes hormones that are released into the bloodstream. Amongst these hormones are the incretins hormones which stimulate the release of insulin from the pancreas which is essential for the regulation of in particular postprandial glucose concen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boer, Geke Aline, Holst, Jens Juul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766765/ https://www.ncbi.nlm.nih.gov/pubmed/33339298 http://dx.doi.org/10.3390/biology9120473

Ejemplares similares

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
por: Holst, Jens Juul, et al.
Publicado: (2020)

Incretin hormones and type 2 diabetes
por: Nauck, Michael A., et al.
Publicado: (2023)

Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture
por: Holst, Jens Juul
Publicado: (2021)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
por: Holst, Jens Juul
Publicado: (2019)

Incretin hormones and the satiation signal
por: Holst, J J
Publicado: (2013)

The Role of Incretins on Insulin Function and Glucose Homeostasis
por: Holst, Jens Juul, et al.
Publicado: (2021)

On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes
por: Sonne, David P, et al.
Publicado: (2014)

Pharmacokinetics of exogenous GIP(1-42) in C57Bl/6 mice; Extremely rapid degradation but marked variation between available assays
por: Boer, Geke Aline, et al.
Publicado: (2021)

Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity
por: Marrano, Nicola, et al.
Publicado: (2021)

Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes
por: Rosenberg, Jared, et al.
Publicado: (2021)

The incretin/glucagon system as a target for pharmacotherapy of obesity
por: Del Prato, Stefano, et al.
Publicado: (2021)

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
por: Holst, Jens J., et al.
Publicado: (2011)

Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes
por: Mari, Andrea, et al.
Publicado: (2013)

Incretins and cardiovascular disease: to the heart of type 2 diabetes?
por: Solini, Anna, et al.
Publicado: (2023)

Comparing olive oil and C4-dietary oil, a prodrug for the GPR119 agonist, 2-oleoyl glycerol, less energy intake of the latter is needed to stimulate incretin hormone secretion in overweight subjects with type 2 diabetes
por: Mandøe, Mette Johannsen, et al.
Publicado: (2018)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
por: Hansen, Katrine B, et al.
Publicado: (2010)

Bone: Incretin Hormones Perceiver or Receiver?
por: Dicembrini, Ilaria, et al.
Publicado: (2012)

The evolving place of incretin-based therapies in type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2010)

Association of Type 2 Diabetes Candidate Polymorphisms in KCNQ1 With Incretin and Insulin Secretion
por: Müssig, Karsten, et al.
Publicado: (2009)

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus
por: Rauch, Thomas, et al.
Publicado: (2012)

Incretin response in Asian type 2 diabetes: Are Indians different?
por: Singh, Awadhesh Kumar
Publicado: (2015)

Incretin Mimetics: Promising New Therapeutic Options in the Treatment of Type 2 Diabetes
por: Gleeson, Jeremy M., et al.
Publicado: (2005)

Incretin hormones as immunomodulators of atherosclerosis
por: Alonso, Nuria, et al.
Publicado: (2012)

Metabolic Effects of the Incretin Mimetic Exenatide in the Treatment of Type 2 Diabetes
por: Schnabel, Catherine A, et al.
Publicado: (2006)

Emerging role of insulin with incretin therapies for management of type 2 diabetes
por: Ahluwalia, Rupa, et al.
Publicado: (2011)

β-Cell Function, Incretin Effect, and Incretin Hormones in Obese Youth Along the Span of Glucose Tolerance From Normal to Prediabetes to Type 2 Diabetes
por: Michaliszyn, Sara F., et al.
Publicado: (2014)

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
por: Schwartz, Stanley, et al.
Publicado: (2010)

Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
por: Khoo, Joan, et al.
Publicado: (2009)

Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus
por: Nisal, Kaustubh, et al.
Publicado: (2012)

Incorporating Incretin-Based Therapies into Clinical Practice for Patients with Type 2 Diabetes
por: Tibaldi, Joseph M.
Publicado: (2014)

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes
por: Yabe, Daisuke, et al.
Publicado: (2011)

Incretin hormone responses to carbohydrate and protein/fat are preserved in adults with sulfonylurea‐treated KCNJ11 neonatal diabetes
por: Bowman, Pamela, et al.
Publicado: (2023)

Molecular mechanisms of incretin hormone secretion()
por: Ezcurra, Marina, et al.
Publicado: (2013)

No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect
por: Mathiesen, David S, et al.
Publicado: (2020)

Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
por: Opazo-Ríos, Lucas, et al.
Publicado: (2020)

Autophagy and Diabetic Encephalopathy: Mechanistic Insights and Potential Therapeutic Implications
por: Cheng, Li-zhen, et al.
Publicado: (2022)

Evolving spectrum of diabetic wound: Mechanistic insights and therapeutic targets
por: Chakraborty, Raja, et al.
Publicado: (2022)

Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
por: Michałowska, Joanna, et al.
Publicado: (2021)

Preserved glucagon-like peptide-1 responses to oral glucose, but reduced incretin effect, insulin secretion and sensitivity in young Asians with type 2 diabetes mellitus
por: Yeow, Toh Peng, et al.
Publicado: (2017)

Incretins in the Therapy of Diabetic Kidney Disease
por: Przezak, Agnieszka, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7a6nuufmpnu0shsi9pv31i8evj